share_log

BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

BTIG将Outlook Therapeutics上调至买入,宣布50美元的目标股
Moomoo 24/7 ·  03/27 07:19

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.

BTIG分析师朱利安·哈里森将Outlook Therapeutics(纳斯达克股票代码:OTLK)从中性上调至买入,并宣布了50美元的目标

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发